RE: Im in12 Dec 2025 07:58
The fact that there is a sell order all the way up at 1.9p shows where many think this will be soon * thats almost 80% from here )
stable foundation for the Group to conclude its strategic review and execute a turnaround plan allowing the Company to progress development plans for both Eroxon® Intense and WSD4000. The Board believes that there is long-term value in the Company's assets and therefore development plans for both Eroxon® Intense and WSD4000 continue to progress. In particular the Board considers that the key issues facing the Company in relation to Eroxon® commercialisation to date are now clear, with plans being developed to manage or mitigate these with the intention of growing shareholder value during 2026.
The Company and Cooper Consumer Health are undertaking a commercial review with regards to the most appropriate market models in the EU. Additionally, the Company is in conversations with Haleon relating to alternative, potentially third party, commercial and distribution strategies and arrangements.